DOCSLIB.ORG

September 28 (Thursday) September the 76Th Annual Meeting of the Japanese Cancer Association Cancer Japanese of the Meeting Annual the 76Th 0-1 1-2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
September 28 (Thursday) September the 76Th Annual Meeting of the Japanese Cancer Association Cancer Japanese of the Meeting Annual the 76Th 0-1 1-2 INFORMATIONDAY 1 AM LS PM Posters DAY 2AMLS PM Posters DAY 3 AMLS PM Posters INDEX Authors Keywords Chairpersons 61 1 Day September 28 (Thursday) The 76th Annual Meeting of the Japanese Cancer Association Cancer Meeting of the Japanese Annual The 76th 0-1 1-2 Core Symposia Symposia Room 1 Sept. 28 (Thu.) 9:00-11:30 E Room 2 Sept. 28 (Thu.) 9:00-11:30 E Translational research based on clinical trials New trends for studying cancer invasion and metastasis CS1 S1 臨床試験からつなげるトランスレーショナルリサーチ がんの浸潤・転移研究の新機軸 Chairpersons: Tony Mok (Chinese Univ. of Hong-Kong) Chairpersons: Nobuyuki Takakura (Dept. of Signal Transduction, RIMD, Osaka Atsushi Ohtsu (Natl. Cancer Ctr. Hosp. East) Univ.) 座長： Tony Mok (Chinese Univ. of Hong-Kong) Hisataka Sabe (Dept. of Mol. Biol., Hokkaido Univ., Grad. Sch. of 大津 敦（国立がん研セ・東病院） Med.) Recent progress on various analytical methods make researchers possible to 座長：高倉 伸幸（大阪大・微研・情報伝達） access precise information of not only tumor itself but tumor microenviron- 佐邊 壽孝（北海道大・院医・分子生物学分野） ment. Next generation sequencer (NGS) panels have changed recent clinical Greater understanding on tumor invasion and metastasis still continuously trial designs like umbrella/basket type studies. Immuno-oncology agents show us a new phase of malignancies of this disease. For example, cancer is have also provided remarkable impacts in cancer therapy, which require fur- now recognized as a metabolic disease, in which the major targets of oncogene ther investigation of immune-related biomarkers including immunity/cross products are cellular metabolism and the reprogramming. Complicated talk in tumor microenvironments for personalized medicine. Considering nature of the cross-talk between cancer cells with stromata, which is to be ini- biomarker researches for clinical applications, investigating clinical samples tiated by cancer cell autonomous alterations of the genome statuses and het- with validated analytical procedure provided from patients enrolled into erogeneity, has also been beginning to be elucidated. In this process, the IND registration clinical trials is an ideal approach. These researches may environmental nutritional supply, at least partly via evoking angiogenesis or additionally yield another new finding in target/drug discovery. lymphangiogenesis, in accordance with metabolic changes of tumor cells In this session, cutting edge translational researches in association with the lat- plays a critical role. Secretion of exosomes from tumors also reprogram est clinical trials will be presented by the five distinguished speakers. The stromal conditions, which often culminate in to help develop tumor malig- attendees will know new findings and directions of translational researches for nancy including distant metastasis. In this session, researchers, who are all spe- precision medicine and the next new target/agent discovery. cialists of these fields of cancer research, will gather together and discuss our future ways to fight so far the incurable nature of cancer for better treat- CS1-1 Biomarker researches for immuno oncology in lung cancer ments. Tony Mok (Chinese University of Hong-Kong) S1-1 Genetic dissection of tumor heterogeneity that triggers cancer CS1-2 RET oncogene fusion: from discovery to clinical trial and progression cancer clinic Tatsushi Igaki (Grad. Sch. of Biostudies, Kyoto Univ.) 1,2 1 2 Takashi Kohno ( Div. Genome Biol., Natl Cancer Ctr Res. Inst., Div. がん原性変異の不均一性が引き起こす腫瘍悪性化の遺伝的基盤 Translational Genomics, EPOC, Natl Cancer Ctr) 井垣 達吏（京大・生命・システム機能学） RET がん遺伝子融合：発見から臨床試験、医療実装へ 河野 隆志 1,2（1 国立がん研究セ・研・ゲノム生物、2 国立がん研究 S1-2 The Arf6 pathway: a major pathway driving the malignancy セ・先端医療開発セ・ゲノム TR） and drug-resistance of refractory cancers Hisataka Sabe, Ari Hashimoto, Yasuhito Onodera, Tsukasa Oikawa, CS1-3 New biomarkers beyond RAS mutation for the treatment of Shigeru Hashimoto (Lab. Mol. Biol., Grad. Sch. Med., Hokkaido Univ.) metastatic colorectal cancer (mCRC) Arf6 経路：難治性癌の悪性度進展・抗癌剤抵抗性に根幹的経路 Takayuki Yoshino (Department of Gastrointestinal Oncology, National 佐邊 壽孝、橋本 あり、小野寺 康仁、及川 司、橋本 茂（北大・院 Cancer Center Hospital East) 医・分子生物学） 切除不能・再発進行大腸癌における新たなバイオマーカー 吉野 孝之（国立がん研究センター東病院 消化管内科） S1-3 Membrane protrusion is enhanced by exosome secretion and drives invasive behavior CS1-4 Biomarker researches in acute leukemia for precision Daisuke Hoshino1, Motoharu Seiki2, Naohiko Koshikawa1 (1Kanagawa medicine Cancer Center Research Institute, 2 Faculty of Medicine, Kanazawa Masashi Sanada (Clinical Research Center, Nagoya Medical Center) University) 白血病に対する最適化医療の実現のためのバイオマーカー研究 エクソソームは細胞膜突起構造を増強し、浸潤活性を惹起する 真田 昌（名古屋医療センター臨床研究センター） 星野 大輔 1、清木 元治 2、越川 直彦 1（1 神奈川県立がんセンター・臨 床研究所、2 金沢大学・医薬保健研究域・医学系） CS1-5 Circulating tumor cells: Detection, Biology and Clinical Implications S1-4 The role of sphingosine-1-phosphate in tumor Klaus Pantel (University Medical Center Hamburg, Institute of Tumor microenvironment and metastasis Biology) Nagahashi Masayuki1, Junko Tsuchida1, Masato Nakajima1, Kazuaki Takabe2, Toshifumi Wakai1 (1Division of Digestive and General Surgery, Niigata University., 2Roswell Park Cancer Institute.) 腫瘍微小環境と転移におけるスフィンゴシン-1-リン酸の役割 永橋 昌幸 1、土田 純子 1、中島 真人 1、高部 和明 2、若井 俊文 1（1 新 潟大学 消化器・一般外科学分野、2 ロズウェルパーク癌がん研究所） S1-5 Tumor vascular promotion by the regulation of LPA4 receptor Nobuyuki Takakura (Dept. of Signal Transduction, RIMD, Osaka Univ.) 腫瘍血管構造の制御によるがん細胞の転移抑制 高倉 伸幸（阪大・微研・情報伝達分野） S1-6 Roles of signaling and transcriptional networks during the formation and maintenance of tumor lymphatic vessels Tetsuro Watabe (Dept. Biochem., Grad. Sch. Med. Dent. Sci., TMDU) 腫瘍リンパ管新生におけるシグナル・転写ネットワークの役割 渡部 徹郎（東医歯大・院医歯総合・硬組織病態生化学） 62 2-3 Room Symposia on Specific Tumors International Sessions 1-4 Room 3 Sept. 28 (Thu.) 9:00-11:30 J Room 4 Sept. 28 (Thu.) 9:00-11:30 E INFORMATION Advances in urological cancer research Cutting edge analysis of exosome in cancer metastasis SST1 IS1 泌尿器科がん研究の最前線 がん転移におけるエクソソーム研究の最前線 Chairpersons: Satoru Takahashi (Dept. Exp. Pathol. Tumor Biol., Nagoya City Chairpersons: Takahiro Ochiya (Natl. Cancer Ctr. Res. Inst.) Univ.) Yong Song Gho (Dept. of Life Sci., Pohang Univ. of Sci. & Tech. Hiroyuki Nishiyama (Dept. of Urology Faculty of Med., Univ. of (POSTECH)) Tsukuba) 座長：落谷 孝広（国立がん研セ・研・分子細胞治療） 座長：高橋 智（名古屋市大・院医・実験病態病理） Yong Song Gho (Dept. of Life Sci., Pohang Univ. of Sci. & Tech. 西山 博之（筑波大・腎泌尿器外科） (POSTECH)) DAY 1 With the development of next generation sequencing technology, analysis of Extracellular vesicles (EV), known as exosomes and microvesicles, serve as the whole genome in cancer are progressing and genetic abnormalities of versatile intercellular communication tools. Increasing evidence has sug- each carcinoma have been clarified. Renal cell carcinoma, the most com- gested that cancer cell-derived exosomes carry pathogenic components. mon malignant tumor of kidney, is known for various histological subtypes, Exosomal transfer of cancer pathogenic components enable long-distance- and each has a characteristic genetic profile. Urothelial carcinoma, derived crosstalk between cancer cells and distant organs and tissues, resulting in AM from mucosa of renal pelvis, ureter and bladder, is classified into two types, the promotion of the initial steps for pre-metastatic niche formation. non-muscle invasive and muscle invasive carcinoma by histological find- Furthermore, the circulating exosome have also been of interest as a source for LS ings and these two subtypes have also distinctively different genetic pro- liquid biopsies. Circulating exosome in body fluids provides a reliable files. Various treatments including molecular targeted or immune-based source of miRNAs, mRNAs, DNAs, proteins, and oncometabolites for cancer PM Posters therapies have been developed based on genetic characteristics of these biomarkers. The tumor-specific components in exosomes effectively pro- tumors, leading to improvement in prognosis. In this symposium, six vide various messages on the physiological and pathological status of cancer experts in the urological cancer field will highlight advanced research patients. In this session, we provide an overview of current research on exo- regarding the molecular mechanisms in the development and progression of somes in cancer, specifically in cancer metastasis, angiogenesis, and drug kidney or bladder cancers which leading to establish the next-generation resistance. We also propose new strategies to purify and classify the exo- therapy. somes and therapy by targeting cancer-specific exosomes. SST1-1 Tumor suppressive role of Hippo signaling in high grade clear IS1-1 Exosome-based cancer diagnostics and therapeutics DAY 2 DAY 3 cell renal cell carcinoma Yong Song Gho (Department of Life Sciences, POSTECH) Masatsugu Moriyama1, Tomoki kai2, Keiko Matsuura3, Takeo Nomura4, Fuminori Satoh4, Hiromitsu Mimata4, Mika Takahashi5 (1Dept. Mol. IS1-2 Induction of drug resistance in vascular endothelial cells by Pathol., Oita Univ., Sch. Med., 2Dept. Urol., Oita Med. Center, 3Dept. highly metastatic tumor-derived exosome Med. Biol., Oita Univ., Sch. Med., 4Dept. Urol., Oita Univ., Sch. Med., Kyoko Hida (Vascular Biology, Inst. Genetic Med., Hokkaido Univ.) AM PM Posters 5Dept. Urol., Beppu Med. Center) 高転移性腫瘍エクソソームによる血管内皮における薬剤耐性誘導 高異型度淡明腎細胞癌における Hippo シグナルの重要性 樋田 京子（北大・遺制研・血管生物） LS 守山 正胤 1、甲斐 友喜 2、松浦 恵子 3、野村 威雄 4、佐藤 文憲 4、三 股浩光4、高橋 美香 5（1 大分大・医・分子病理、2 大分医療セ・泌、 IS1-3 Emerging roles of exosomes as nucleic acid carriers and potential impacts as trans-genomic agents 3 大分大・医・医学生物、4 大分大・医・泌、5 別府医療セ・泌） Yumi Kawamura1,2, Yusuke Yamamoto1, Taka-Aki Sato2, Takahiro SST1-2 Clarification
Load more

Recommended publications
  • International Session Poster 一般ポスター
    Web 閲覧 International Session Poster 一般ポスター ※本プログラムの演題名・氏名・所属の表記は、ご自身による表記を 優先いたしましたが、統一のため多少変更を加えた部分があります。 KLQSBWZHELQGG KLQSBWZHELQGG International Session Poster 01 ◆ Andrology ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-01 Withdrawn ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-02 Results of Assisted Reproductive Treatment in Azoospermic Patients Batmunkh Ganbat（Infertility and Reproductive Center, Mongolian National Center for Maternal and Child Health, Mongolia） ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-03 Bilateral inguinal hernia diagnosed and treatment on laparoscopic varicocelectomy Erdenebaatar Baljinnyam（Surgical Department, MD, Surgeon of Central Hospital of Arkhangai Aimag, Mongolia） ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • Fine Tuning HCN Channel Activity Tural Basis of This Coupling Has Only Been Well Characterized in Kcsa
    Wednesday, February 15, 2017 465a Symposium: Protein Dynamics and Allostery example, in-silico models of human cardiac electrophysiology are being considered by the FDA for prediction of proarrhythmic cardiotoxicity as a 2285-Symp core component of the preclinical assessment phase of all new drugs. How- Coupled Residue-Residue Dynamics in Protein Allosteric Mechanisms ever, one issue that exists with current models is that they each respond Donald Hamelberg. differently to insults such as drug block of ion channels or mutation of cardiac Department of Chemistry, Georgia State University, Atlanta, GA, USA. ion channel genes. Clearly this poses a problem in relation to the utility of Although the relationship between structure and function in biomolecules is these models in making quantitative predictions that are physiologically or well established, it is not always adequate to provide a complete understanding clinically meaningful. To examine this in detail we tested the ability of three of biomolecular function. The dynamical fluctuations of biomolecules can also models of the human ventricular action potential, the O’hara-Rudy the Grandi- play an essential role in function. Detailed understanding of how conforma- Bers and the Ten Tusscher models, to reproduce the clinical phenotype of tional dynamics orchestrates function in allosteric regulation of recognition different subtypes of the long QT syndrome. All models, in their original and catalysis at atomic resolution remains ambiguous. The overarching goal form, produce markedly different and unrealistic predictions of QT prolonga- is to understand how biomolecular dynamics are coupled to function by using tion. To address this, we used a global optimization approach to constrain ex- atomistic molecular simulations to complement experiments.
    [Show full text]
  • CNPY2 Inhibits MYLIP-Mediated AR Protein Degradation in Prostate Cancer Cells
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 25), pp: 17645-17655 Research Paper CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells Saya Ito1,*, Akihisa Ueno1,*, Takashi Ueda1,2, Hideo Nakagawa1, Hidefumi Taniguchi1, Naruhiro Kayukawa1, Atsuko Fujihara-Iwata1, Fumiya Hongo1, Koji Okihara1 and Osamu Ukimura1 1Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto-City, Kyoto 602-8566, Japan 2Department of Urology, Uji Takeda Hospital, Uji-City, Kyoto 611-0021, Japan *These authors equally contributed to this work Correspondence to: Takashi Ueda, email: [email protected] Keywords: CNPY2; prostate cancer; AR; MYLIP; protein degradation Received: September 29, 2017 Accepted: March 01, 2018 Published: April 03, 2018 Copyright: Ito et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT The androgen receptor (AR) is a ligand-dependent transcription factor that promotes prostate cancer (PC) cell growth through control of target gene expression. This report suggests that Canopy FGF signaling regulator 2 (CNPY2) controls AR protein levels in PC cells. We found that AR was ubiquitinated by an E3 ubiquitin ligase, myosin regulatory light chain interacting protein (MYLIP) and then degraded through the ubiquitin-proteasome pathway. CNPY2 decreased the ubiquitination activity of MYLIP by inhibition of interaction between MYLIP and UBE2D1, an E2 ubiquitin ligase. CNPY2 up-regulated gene expression of AR target genes such as KLK3 gene which encodes the prostate specific antigen (PSA) and promoted cell growth of PC cells.
    [Show full text]
  • October 7 (Friday) October 7 the 75Th Annual Meeting of the Japanese Cancer Association Cancer Japanese of the Meeting Annual the 75Th Room 4 Oct
    INFORMATION The 75th Annual Meeting of the Japanese Cancer Association DAY 1 AM PM Day 2 LS October 7 (Friday) Posters DAY 2 AM LS PM Posters DAY 3 AM PM Posters LS INDEX Authors Keywords Chairpersons 125 Room 4 Oct. 7 (Fri.) 8:00-8:50 E Room 8 Oct. 7 (Fri.) 8:00-8:50 J Potential cancer therapeutics targeting TGF-β/Smad3 From Real-time Tumor-Tracking Technology to Motion ML1 signaling ML5 Science in Life 動体追跡技術から生体の動きの科学へ Chairperson: Susumu Itoh (BioChem., Showa Pharm. Univ.) 座長：伊東 進（昭和薬大・生命薬学・生化学） Chairperson: Masahiko Miura (Tokyo Med. & Dent. Univ.) 座長：三浦 雅彦（東京医歯大・院医歯・口腔放射線腫瘍） ML1 Potential cancer therapeutics targeting TGF-β/Smad3 signaling ML5 From Real-time Tumor-Tracking Technology to Motion Seong-Jin Kim1, Eunjin Bae1, Jinah Park1, Mi-Kyung Kwak1, Kazuhito Science in Life Naka2, Ooshima Akira1 (1Nanobio Med. Res. Ctr., AICT, Seoul Natl. Hiroki Shirato1,2 (1Dept. Radiat. Med., Grad. Sch. Med. Hokkaido Univ., Univ., 2Res. Inst. for Radiation Biol. & Med., Hiroshima Univ.) 2Quant. Med. Sci. Eng., Glob. Inst. Res. Ed., Hokkaido Univ.) 動体追跡技術から生体の動きの科学へ 白土 博樹 1,2（1 北海道大・医・放医、2 北海道大・国際連携・量子医 理工） Room 5 Oct. 7 (Fri.) 8:00-8:50 J Room 9 Oct. 7 (Fri.) 8:00-8:50 J RUNX genes: Integral component of Fanconi-BRCA pathway In situ Delivery and Production System(iDPS) to Target ML2 ML6 Hypoxia of Solid Cancers with Anaerobic Bifidobacterium 嫌気性ビフィズス菌を用いた固形がんの嫌気的環境を標的とする選択的・持続的抗がん物質の産生系 Chairperson: Rieko Ooki (Natl. Cancer Ctr.) 座長：大木 理恵子（国立がん研究セ・研・難治がん） Chairperson: Shinae Kondoh (Sch. of Life Sci. &d Tech., Tokyo Inst.
    [Show full text]
  • RIKEN IMS Annual Report  RIKEN Center for Integrative Medical Sciences  T Jp English/ Jp
    RIKEN IM S Annual RIKEN Center for Repo Integrative Medical Sciences http://www.ims.riken.jp/english/ r t RIKEN Yokohama Campus 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan RIKEN Center for Integrative Medical Sciences Integrative Medical for Center RIKEN Tel : 045-503-9111 Fax : 045-503-9113 Email : [email protected] RIKEN IMS Annual Report RIKEN IMS Annual Report RIKEN Center for Integrative Medical Sciences RIKEN - RIKEN Center for Integrative Medical Sciences Access to RIKEN Yokohama Campus Organization Chart Local Access RIKEN President By Bus Take the #08 bus from Platform 8 at the East Exit of Hiroshi Matsumoto Tsurumi Station (also accessible from the West Exit of Keikyu Tsurumi Station) and get off at the RIKEN Shidai Daigakuin Mae bus stop. The institute is across the street. All buses from this platform are bound for Fureyu. Director Buses depart Tsurumi every 5–15 minutes. It takes about 15 minutes to arrive at RIKEN Yokohama. The Tadashi Yamamoto fare is 220 yen. By Train A 15-minute walk from JR Tsurumi-Ono Station (JR Tsurumi Line), which is directly accessible by transfer Integrative Senior Advisor from JR Tsurumi Station. Medical Sciences rains run about every 10 minutes during morning and Planning Oce Masaru Taniguchi evening rush hour, but less frequently at other times. Shizuo Akira Searchable train timetables in English are available at http://www.hyperdia.com/en/ By Taxi Use the taxi stand at the East Exit of JR Tsurumi Station or the West Exit of Keikyu Tsurumi Station. The trip takes about 10 minutes and costs around 1,200 yen.
    [Show full text]